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Abstract
Background: Major drawbacks of the available treatment against Chagas disease (American trypanosomiasis)
include its toxicity and therapeutic inefficiency in the chronic phase of the infection, which makes it a concern
among neglected diseases. Therefore, the discovery of alternative drugs for treating chronic Chagas disease requires
immediate action. In this work, we evaluated the mushroom Pleurotus salmoneostramineus in the search for
potential antiparasitic compounds.
Methods: Fruit bodies of the basidiomycete Pleurotus salmoneostramineus were triturated and submitted to organic
solvent extraction. After liquid-liquid partition of the crude extract, three fractions were obtained and the bioguided
fractionation study was conducted to isolate the active metabolites. The elucidation of the chemical structure was
performed using GC-MS and NMR techniques. The biological assays for antiparasitic activity were carried out using
trypomastigotes of Trypanosoma cruzi and murine macrophages for mammalian cytotoxicity. The mechanism of
action of the isolated compound used different fluorescent probes to evaluate the plasma membrane permeability,
the potential of the mitochondrial membrane and the intracellular levels of reactive oxygen species (ROS).
Results: The most abundant fraction showing the antiparasitic activity was isolated and chemically elucidated,
confirming the presence of ergosterol. It showed anti-Trypanosoma cruzi activity against trypomastigotes, with an
IC50 value of 51.3 μg/mL. The compound demonstrated no cytotoxicity against mammalian cells to the maximal
tested concentration of 200 μg/mL. The mechanism of action of ergosterol in Trypanosoma cruzi trypomastigotes
resulted in permeabilization of the plasma membrane, as well as depolarization of mitochondrial membrane
potential, leading to parasite death. Nevertheless, no increase in ROS levels could be observed, suggesting damages
to plasma membrane rather than an induction of oxidative stress in the parasite.
Conclusions: The selection of naturally antiparasitic secondary metabolites in basidiomycetes, such as ergosterol,
may provide potential scaffolds for drug design studies against neglected diseases.
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Background
Chagas disease (CD) was described in 1909 by the Brazilian
researcher Carlos Ribeiro Justiniano das Chagas [1]. It is
currently estimated that 8 million people are infected
worldwide, especially in 21 countries of Latin America. CD
is responsible for 10,000 deaths annually, being a risk for
100 million people [2]. In Brazil, prevalent chronic cases of
CD result from infections acquired in the past, affecting
approximately three million individuals [2, 3]. However, in
recent years, the occurrence of acute Chagas disease
(ACD) has been observed in the Amazon, with the mani-
festation of isolated cases in other states [4]. Trypanosoma
cruzi is the etiologic agent of CD, a hemoflagellate proto-
zoan from the Kinetoplastida order [5]. Although CD has
been described more than 100 years ago, the chemother-
apy is, so far, limited to two nitro-heterocyclic drugs: benz-
nidazole and nifurtimox [6]. Both are effective in the acute
phase of the infection, with approximately 60–80% efficacy
[7]. However, they are considered far from ideal in the
chronic phase of the disease, with severe adverse effects
and reduced efficacy [7, 8].
Due to this toxic and limited therapeutic arsenal, there is
an urgent need to find new drugs. Considering that natural
products have been providing interesting scaffolds for
protozoan diseases, herein we investigated the potential of
basidiomycetes, a rich source for antimicrobial compounds.
For example, hypnofylline and panepoxidone isolated from
the basidiomycete Lentinus strigosus and an ergosterol per-
oxide isolated from Pleurotus ostreatus have demonstrated
anti-T. cruzi activities [9, 10]. Considering the genus Pleur-
otus, a number of secondary metabolites have been isolated
with different biological properties, such as antitumor,
antileishmanial, antimicrobial, anti-inflammatory and anti-
trypanosomal activities among others [10–14].
To the best of our knowledge, this is the first study
that identified the antiparasitic potential of Pleurotus
salmoneostramineus – popularly known as the “pink
mushroom” – that grows on leaves of senescent plants
found in Japan, New Guinea and Siberia. It is a popular
mushroom because of the colorful body, flavor and tex-
ture, being rich in proteins, lipids, fiber, carbohydrates,
vitamins and essential amino acids. It is generally used
in reducing plasma cholesterol levels and prevents ath-
erosclerosis [15, 16]. By using the bioguided fraction-
ation, we isolated and chemically characterized the most
abundant metabolite of P. salmoneostramineus with anti-
trypanosomal activity and evaluated its action on the
plasma membrane, mitochondria and ROS levels of try-
pomastigote forms of the parasite.
Methods
Basidiomycete and chemicals
The basidiomycete Pleurotus salmoneostramineus was
commercially purchased from Zucca Funzionale (Brazil)
and its identification was confirmed by the Adolfo Lutz
Institute. Phosphate-buffered saline (PBS), Roswell Park
Memorial Institute Medium (RPMI 1640), Hank’s Bal-
anced Salt Solution (HBSS), sodium azide, Triton X-100,
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP), miltefosine, benznidazole (2-nitroimidazole),
and the solvents dimethyl sulfoxide (DMSO), methanol
(MeOH), hexane, ethyl acetate (EtOAc), butanol and di-
chloromethane were purchased from Sigma. The TLC
Siligel 60 F254 aluminum chromatoplates with fluores-
cence indicators and common silica were purchased
from Merk. Resazurin, sodium dodecyl sulfate (SDS),
Sytox Green dye, Mitotracker Red CM-H2XROS,
H2DCf-DA and MTT were purchased from Molecular
Probes® (Invitrogen).
Parasites, mammalian cells and experimental animals
Trypomastigotes of Trypanossoma cruzi (Y strain) were
maintained in LLC-MK2 (ATCC CCL 7) cells using
RPMI-1640 medium supplemented with 2% fetal bovine
serum (FBS) at 37 °C in 5% CO2 humidified incubator.
LLC-MK2 (ATCC) cells were maintained in RPMI-1640
medium without phenol red and supplemented with
10% SBF at the same conditions [17]. Peritoneal macro-
phages were collected from the peritoneal cavity of fe-
male BALB/c mice by washing with RPMI-1640 without
phenol red, supplemented with 10% FBS. BALB/c mice
were supplied by the animal breeding facility at the
Adolfo Lutz Institute and maintained in sterilized cages
under a controlled environment, receiving water and
food ad libitum. Animal procedures were performed
with the approval of the Research Ethics Commission
(CEUA-IAL-Pasteur 01/2011), in agreement with the
Guide for the Care and Use of Laboratory Animals from
the National Academy of Sciences.
Crude extract and liquid-liquid partition
Fruit-bodies of mushrooms basidiomycete P. salmoneos-
tramineus (1000 g) were triturated and extracted with
1.4 L MeOH:H2O solution (1:1 v/v). This solution was
sonicated (10 min), filtered (Whatman filter) and evapo-
rated at 40 °C resulting in the crude extract. Subse-
quently, the crude extract was resuspended in 400 mL of
water and partitioned using growing polarity solvents to
afford the three fractions, n-hexane (518.8 mg), EtOAc
(3432.9 mg) and butanol (1923.2 mg). Then, these frac-
tions were dried at 40 °C and stored at –20 °C until
analysis.
Determination of 50% inhibitory concentration (IC50)
against Trypanosoma cruzi
To determine the 50% inhibitory concentration (IC50)
against free trypomastigotes of T. cruzi obtained from
LLC-MK2 cultures, 1 × 106 parasites/well were seeded
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on 96-well microplates. N-hexane, EtOAc and butanol
fractions were dissolved in MeOH, serially diluted (two-
fold) in RPMI-1640 medium and incubated with the par-
asites in a range concentration between 300 and 2.3 μg/
mL (final volume 200 μL) for 24 h, 37 °C, 5% CO2. At
the same conditions, the isolated compound was dis-
solved in DMSO, serially diluted (two-fold) and added to
the highest concentration of 150 μg/mL. Benznidazole
was used as a standard drug in a range concentration
between 100 and 0.78 μg/mL. The parasite viability was
determined by resazurin assay (0.11 mg/mL in PBS, 20 h
incubation) using the FilterMax F5 Multi-Mode Micro-
plate Reader, Molecular Devices (Sunnyvale, CA, USA),
at 570 nm [18]. DMSO was used to dissolve the com-
pounds and was included in the microplate at 0.5% (v/v)
to avoid toxicity. Internal controls were also performed
with DMSO. Additionally, the lethal effect of the isolated
compound was confirmed on trypomastigotes using
classical light microscopy analysis [19].
To determine the IC50 against intracellular amastigotes
of T. cruzi, peritoneal macrophages were dispensed in
16-well chamber slide (NUNC, Thermo, USA) and
maintained for 24 h in the same medium at 37 °C in a
5% CO2 humidified incubator for attachment. Non ad-
herent cells were removed by two-step washings with
medium. After 24 h, these cells were infected with 1 ×
106 culture trypomastigotes forms for 4 h. Subsequently,
infected cells were incubated with the ergosterol in a
range concentration between 100 and 0.78 μg/mL (final
volume 200 μL) for 48 h. Finally, the slides were fixed
with methanol, stained with Giemsa, and observed in a
light microscope. The parasite load was defined by
counting 400 macrophages/well by evaluating the num-
ber of infected macrophages. Benznidazole was used as
standard drug in a range concentration between 50 and
0.39 μg/mL. DMSO was used at a maximal concentra-
tion of 0.5% (v/v) and incubated with cells as an internal
control [20].
Bioguided fractionation
The anti-trypomastigote activity guided the fractionation
procedures. n-hexane, EtOAc and butanol fractions were
subjected to thin layer chromatography (TLC) in
aluminum plates of silica gel 60 F254 TLC with a fluores-
cent indicator at 254 nm. 1H and 13C RMN analysis,
with spectra recorded at 300 and 75 MHz, were per-
formed using a Bruker Ultrashield 300 Avance III spec-
trometer, respectively. CDCl3 (Aldrich) was used as the
solvent with TMS as the internal standard. Chemical
shifts (δ) are reported in ppm and the coupling constant
(J) in Hz. n-hexane fraction were subjected to column
chromatography (CC) with 89 g of silica gel G-60 (Merk,
0.063-0.200 mm) and 510 mg n-hexane fraction (CPS –
column Pleurotus salmoneostramineus). Solvent system
started with pure n-hexane (10:0, v/v) to pure EtOAc
(0:10, v/v, 50 mL), followed by increasing amounts of
MeOH (EtOAc 9:1, v/v to pure MeOH 0:10, v/v). New
fractions obtained from this process (50 mL) were dried
at 40 °C and stored at –20 °C until analysis. Structural
elucidation of fraction CPS-3(3) were performed by ana-
lysis 1H and 13C RMN and GC-MS.
Cytotoxicity against mammalian cells
To determine the 50% cytotoxic concentration (CC50) of
the isolated compound, it was previously dissolved in
DMSO, serially diluted (two-fold) in RPMI-1640
medium-10% SBF at maximum concentration of 200 μg/
mL and incubated with 6 × 104 peritoneal macrophages
seeded on 96-well microplates, final volume of 200 μL
during 48 h, 37 °C 5% CO2. Cell viability was determined
by resazurin assay as above described. Same conditions
were applied to determine the CC50 of the standard drug
benznidazole, which was tested in a range concentration
between 200 and 1.56 μg/mL [21]. DMSO was used to
dissolve the compounds and was included in the micro-
plate at 0.5% (v/v) to avoid toxicity. Internal controls
were also performed with DMSO.
Hemolytic activity
The hemolytic activity of the isolated ergosterol was
evaluated in BALB/c erythrocytes [22]. A 3% suspension
of mouse erythrocytes was incubated for 2 h with the
isolated compound at 100 μg/mL in 96-well U-shape mi-
croplate at 25 °C and the supernatant was read at
550 nm in a spectrophotometer FilterMax F5 Multi-
Mode Microplate Reader, Molecular Devices (USA). Ul-
trapure distilled water was used as a positive control
(100% hemolysis) and phosphate-buffered saline (PBS)
as a negative control (0% hemolysis). DMSO was also
used at 0.5% as internal control.
Mechanism of action of ergosterol
As standard conditions, free trypomastigotes of T. cruzi
obtained from LLC-MK2 cultures were washed twice
and seeded on 2 × 106/well in PBS to 96-well black poly-
styrene microplate. The isolated compound was tested at
the IC99 value (100 μg/mL) and incubation was per-
formed at 37 °C, 5% CO2. Fluorescence was monitored
using FilterMax F5 Multi-Mode Microplate Reader,
Molecular Devices (USA) at respective wavelengths. In
all mechanism assays, the following internal controls
were used in presence of respective dyes (Sytox Green,
MitoTracker Red CM-H2XROS or H2DCf-DA): the
background fluorescence of the isolated compound at
the respective wavelengths; the possible interference of
DMSO; untreated (control) trypomastigotes; and
medium without any cells. Samples were tested in
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triplicate and at least three independent assays were
performed.
Evaluation of plasma membrane permeability
Under standard conditions, trypomastigotes were incu-
bated with 1 μM Sytox Green for 15 min at 37 °C, 5%
CO2 in the dark [23]. Then, the isolated compound was
added at 100 μg/mL and the fluorescence was monitored
every 20 min during 80 min at excitation (λex) and
emission (λem) wavelengths of 485 and 520 nm, respect-
ively. The maximum membrane permeabilization was
obtained with 0.5% Triton X-100, as a positive control.
Evaluation of the mitochondrial membrane potential
Under standard conditions, trypomastigotes were incu-
bated with the isolated compound at 100 μg/mL during
60 min and then MitoTracker Red CM-H2XROS (500
nM) was added and incubated for 40 min in dark. The
minimal mitochondrial membrane potential was ob-
tained by treatment of trypomastigotes with 10 μM
FCCP, a known mitochondrial uncoupler. Trypomasti-
gotes were washed twice with PBS before fluorescence
reading at λex = 540 nm and λex = 595 nm [21].
Detection of reactive oxygen species (ROS)
Intracellular ROS levels were measured using fluorescent
probe H2DCf-DA. Under standard conditions, except by
the use of HBSS solution instead of PBS, trypomasti-
gotes were incubated with the isolated compound ergos-
terol at 100 μg/mL and sodium azide (10 mM) as a
positive control in order to obtain high levels of ROS
production during 60 min. Then, fluorescent probe
H2DCf-DA was added (5 μM, 15 min) and the fluores-
cence intensity measured at λex = 485 nm and λex =
520 nm [23].
Statistical analysis
The IC50 and CC50 values were calculated using sigmoid
dose-response curves in GraphPad Prism 5.0 software,
and the 95% confidence intervals are included in paren-
theses. The ANOVA test was used for significance p
value. The data obtained from the mechanism of action
represent the mean and standard deviation (SD) of tripli-
cate samples from at least two independent assays.
Results
Bioguided fractionation and antitrypanosomal activity
The three obtained fractions (n-hexane, EtOAc and bu-
tanol) were incubated with free trypanosomes during 24
ho and the viability determined by the resazurin assay.
All fractions demonstrated anti-trypomastigote activity
against the parasite resulting in 100% of death at the
highest concentration of 300 μg/mL. The n-hexane,
EtOAc and butanol fractions showed IC50 values of
7.9 μg/mL, 28.0 μg/mL and 58.3 μg/mL, respectively
(Table 1). The TLC analysis determined a good reso-
lution for the mixture of n-hexane:EtOAc (1:1, v/v) (data
not shown). Together, the analytical assays and the anti-
trypomastigote activity of n-hexane fraction guided the
subsequent separations, yielding 17 new fractions, which
were compiled into ten groups (CPS1-10) based on their
chromatographic similarities. The antitrypanosomal ac-
tivity was detected in a crystallized fraction [namely
CPS-3(3)], which resulted in an IC50 value of 51.3 μg/
mL (46.1–57.0) against the trypomastigotes (Table 1).
Biological activity of ergosterol
The viability of trypamastigotes of T. cruzi and mamma-
lian cells treated with ergosterol was determined by resa-
zurin and MTT assay after 48 h of incubation.
Ergosterol showed a moderate anti-trypomastigote activ-
ity with IC50 = 51.3 μg/mL; benznidazole was used as
standard drug and resulted in an IC50 = 4.4 μg/mL. Add-
itionally, light microscopy analysis confirmed the lethal
effect of ergosterol in trypomastigotes. Ergosterol was
also tested against the intracellular amastigotes of T.
cruzi, but demonstrated no activity. Ergosterol (and
benznidazole) showed lack of toxicity to BALB/c peri-
toneal macrophages to the maximal tested concentration
of 200 μg/mL (Table 1). The hemolytic activity of ergos-
terol was tested in mice erythrocytes, but the compound
induced no significant hemolysis (7.03% ± 11.6) to the
highest tested concentration (Table 1) when compared
to untreated cells.
Ergosterol structural elucidation
The CPS-3(3) fraction was subjected to 1H and 13C
RMN and GC-EI-MS analysis for structural elucidation.
13C RMN spectra reveals C28-sterol ergostane skeleton,
including signals of six unsaturated carbonsat δC 116.3-
Table 1 Antitrypanosomal activity of ergosterol and cytotoxicity against mammalian cells
Compound IC50 (μg/mL)
95% CI
trypomastigote
IC50 (μg/mL)
95% CI
amastigote
CC50 (μg/mL)
95% CI
macrophages
Selectivity index Hemolytic activity (SD)
Ergosterol 51.3 (46.0–57.0) >100 > 200 > 3.9 7.03% (±11.6)
Benznidazole 4.4 (3.7–5.1) 1.9 (1.2–2.3) > 200 > 45.0 nd
IC50: 50% effective concentration; CC50: 50% cytotoxic concentration; 95% CI: 95% confidence interval; SI: selectivity index calculated as (SI = CC50 mammalian cell/
IC50 trypomastigotes); nd: not determined
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141.4 corresponding to C-5 (δC 139.8); C-6 (δC 119.6),
C-7 (δC 116.3), C-8 (δC 141.4), C22 (δC 135.6) and C23
(δC 131.9). Methyl carbons were observed in C-18 (δC
12.1), C-19 (δC 16.3), C-21 (δC 21.1) C-26 (δC 28.3), C-
27 (δC 19.7) and C-28 (δC 17.6), whereas hydroxyl group
was observed in C-3 (δC 70.5).
1H RMN corroborated
sterol Δ5,7 structure by signals δH 5.58 (dd, J = 3.0;
5.5 Hz) and 5.38 (dd, J = 2.9; 5.4 Hz) diagnostic for olefin
hydrogens H-6 and H-7, besides multiplet in δH 3.64
(H-3) indicate the presence of hydrogen linked to carbi-
nolic carbon. Double bonds were observed at signal 5.20
(m) relative to H-22 and H-23. Still, signals at region δH
0.8 and 1.1 relative to methyl groups identified two
singlet hydrogen in δH 0.95 (CH3-C-18) and 0.65 (CH3-C-
19), and four duplets in δH 0.82 (CH3-27), 0.84 (CH3-26);
0.92 (CH3-28), 1.04 (CH3-21). The assignment of all the
carbon signals was performed by comparison with the re-
ported data (Table 2). Table 1 compiles 1H and 13C RMN
comparing with literature [24, 25].
GC-EI-MS also confirmed the identity and purity of
ergosterol (Fig. 1) by the presence of m/z 396 corre-
sponding to molecular formula C28H44O and fragments
m/z 378 [M–H2O]
+, m/z 363 [M–CH3-H2O]
+, m/z 253
[M–side chain-H2O]
+ and m/z 271 [M–side chain]+, a
typical fragmentation profile of sterols [26] (Additional
file 1).
Permeabilization of plasma membrane
Ergosterol (at IC99 100 μg/mL) was incubated for
80 min with trypomastigotes and the permeability of
plasma membrane was evaluated through the fluores-
cence of Sytox Green dye (1 μM). The entrance of Sytox
Table 2 13C and 1H RMN data for ergosterol (75 MHz and 300 MHz)
Position δC EXP δC LIT.a δH EXP δH LIT.b
1 38.4 38.5
2 31.9 32.1
3 70.5 70.5 3.64 m (1H) 3.61 m (1H)
4 40.8 40.9
5 139.8 139.8
6 119.6 119.7 5.58 dd (5.5, 3.0 Hz, 1H) 5.56 dd (5.4, 2.2 Hz, 1H)
7 116.3 116.4 5.38 dd (5.4, 2.9 Hz, 1H) 5.38 dd (5.4, 2.5 Hz, 1H)
8 141.4 141.3
9 46.2 42.3
10 37.1 37.1
11 21.1 21.1
12 39.1 39.1
13 42.9 42.9
14 54.6 54.6
15 22.9 23.1
16 28.3 28.3
17 55.7 55.8
18 12.1 12.1 0.95 s (3H) 0.95 s (3H)
19 16.3 16.3 0.65 s (3H) 0.63 s (3H)
20 40.3 40.4
21 21.1 21.2 1.04 d (J = 6.6 Hz, 3H) 1.00 d (J = 6.6 Hz, 3H)
22 135.6 135.6 5.20 m (1H) 5.20 m (1H)
23 131.9 132.1 5.21 m (1H) 5.20 m (1H)
24 42.9 42.9
25 33.1 33.1
26 19.9 20.0 0.84 d (J = 6.7 Hz, 3H) 0.84 d (J = 6.7 Hz, 3H)
27 19.7 19.7 0.82 d (J = 6.7 Hz, 3H) 0.83 d (J = 6.7 Hz, 3H)
28 17.6 17.6 0.92 d (J = 6.6 Hz, 3H) 0.95 d (3H)
a [21]
b [22]
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Green dye is allowed solely in injured plasma membrane,
otherwise, its influx is precluded and no fluorescence
can be measured. The increase of the dye caused by er-
gosterol (Fig. 2) were significant (p < 0.002) compared to
untreated parasites, suggesting the alteration of the
plasma membrane permeability when compared to the
positive control with 0.5% Tx100 (p < 0.001), a non-ionic
detergent (Fig. 2).
Alteration of mitochondrial membrane potential
Alteration in mitochondrial membrane potential was de-
termined by the fluorescence of Mitotracker Red CM-
H2XROS dye (500 nM) in trypomastigotes treated with
ergosterol (100 μg/mL) for 60 min. Ergosterol treatment
caused significant decreased in the accumulation of
Mitotracker Red at mitochondria indicating an effect of
depolarization since normal potential guided maximal
accumulation of dye in untreated trypomastigotes (con-
trol). Mitochondrial dysfunction promoted by ergosterol
was comparable to that achieved by the treatment with
10 μM FCCP (Fig. 3).
Reactive oxygen species (ROS) production
The production of ROS in trypomastigotes incubated
with ergosterol (60 min, 100 μg/mL) was evaluated by
the fluorescence of H2DCF-DA dye (5 μM). Trypomasti-
gotes treated with ergosterol showed no significant in-
crease in the production of ROS, showing levels similar
to the untreated parasites. Trypomastigotes treated with
sodium azide (10 mM) showed intense fluorescence as a
positive control (Fig. 4).
Discussion
Natural secondary metabolites isolated from basidiomy-
cetes have been described as rich source of bioactive
molecules. Terpenoids isolated from Lentinus strigosus
and lanostane-type triterpenes isolated from Astraeus
hygrometricus are some examples of compounds with
Fig. 1 Structure of ergosterol confirmed by 13C, 1H RMN and GC-EI-MS
Fig. 2 Effect of ergosterol on plasma membrane permeabilization of trypomastigotes of T. cruzi. Sytox Green (1 μM) fluorescence was measured
spectrofluorimetrically every 20 min. Minimum and maximum permeabilization were obtained by non-treatment and Tx-100 0.5%, respectively.
Fluorescence was quantified by calculating the mean percentages of untreated (0%) and Tx-100-treated (100%) trypomastigotes. *** p < 0.001 and
**p < 0.002. A representative assay is shown
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promising activity against protozoan parasites such as T.
cruzi and Leishmania [9, 24, 27].
Few studies on the chemical composition of mush-
rooms Pleurotus salmoneostramineus have been per-
formed whereas the evaluation of their biological
activities remains underexplored [15, 28, 29]. In the
present study, the fractionating of the organic crude
extract of P. salmoneostramineus yielded an antitrypano-
somal substance. Our initial data demonstrated the pres-
ence of antiparasitic compounds in fractions of different
polarities, such as n-hexane, EtOAc and butanol, which
suggests that no single compound exists with efficacy
against T. cruzi parasites. Among them, the ergosterol
was isolated in large amount as a crystalized pure sub-
stance further elucidated by NMR and GC-EI-MS based
in the literature data [24–26].
Ergosterol is the major sterol that composes mem-
branes of T. cruzi parasites – including plasma, inner
mitochondrial and glycosomal membranes – instead of
cholesterol, its counterpart in mammalian cells that is
usually confined to the plasma membrane [30–32]. Try-
panosoma cruzi normally synthesizes sterols and occa-
sionally leucine from carbon precursors [33]. The
singularity of the sterol composition of T. cruzi parasites
– closest to fungi cells than to mammalian host cells –
has validated SBP as target for new therapeutic drugs
[34]. Indeed, T. cruzi CPY51 (TcCPY51) inhibitors –
posaconazole and ravuconazole – entered in Drugs for
Neglected Diseases Initiative (DNDi) clinical trials for
Chagas disease despite the clinical failure recently re-
ported [35, 36]. In general, the efficacy of TcCYP51 in-
hibitor has been considerably variable depending on the
parasite strain and time of exposure [36, 37].
In addition to TcCYP51 inhibitors, sterols isolated
from different natural sources including plants, marine
sponges and amphibians have demonstrated to present
antiprotozoan activities. Interestingly, ergosterol itself
can be trypanocidal at unusual levels from its natural
metabolism [22, 38, 39]. For example, T. cruzi amasti-
gotes had 94% of growth inhibited by 10 μM of
ergosterol [40]. A previous study demonstrated that
ergosterol peroxide, but not ergosterol, isolated from the
basidiomycete Pleurotus ostreatus also presented anti-T.
cruzi activity, with an IC50 value of 6.7 μg/mL against
the insect form, epimastigotes [10]. When compared to
our results, the previous work suggests that ergosterol
peroxide is approximately 8-fold more active than ergos-
terol against trypomastigote forms. This could be due to
the presence of the endoperoxide group, a known struc-
ture presenting potential biological properties [41, 42].
Additionally, differences may rely on metabolic speci-
ficities among forms of T. cruzi. For example, extracellu-
lar epimastigotes found in the insect vector have been
described to be more susceptible to drugs than trypo-
mastigotes, a parasite form found inside cells and blood-
stream of vertebrate hosts [43]. Relapse and therapeutic
failure have been described to arise from resident trypo-
mastigotes, usually not affected by conventional therapy,
which preferentially target intracellular amastigotes [44].
This information highlight the importance of selecting
new anti-trypomastigote compounds.
The lethal action of ergosterol against trypomastigotes
of T. cruzi was investigated. Ergosterol-treated trypomasti-
gotes showed a rapid plasma membrane permeabilization
as determined by the Sytox Green fluorescence. Alter-
ations in plasma membrane composition are known to
Fig. 3 Effect of ergosterol in the mitochondrial function of
trypomastigotes. Fluorescence of Mitotracker Red CM-H2XROS
dye (500 nM) was spectrofluorimetrically measured after 60 min
of incubation. Maximal and minimal fluorescence was achieved
by non- or FCCP (10 μM) treatments, respectively. Fluorescence
was quantified by calculating the mean percentage of untreated
parasites (100%). *p < 0.001. A representative assay is shown
Fig. 4 Effect of ergosterol in the ROS production of trypomastigotes.
Fluorescence of H2DCF-DA was measured after 60 min of incubation.
Fluorescence was quantified by calculating the mean percentage of
untreated (0%) and sodium azide-treated (100%) trypomastigotes.
***(p < 0.001). A representative assay is shown
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modify fluidity and cellular morphology. For example,
high concentrations of ergosterol have been speculated to
be associated with rigidity, whereas low concentrations
cause disorganization/disruption of the plasma membrane
[45–47]. In our work, the physicochemical properties of
ergosterol may have contributed to its crossing through
plasma membrane, thus rapidly altering the permeability
by disturbing normal lipid composition and modifying its
fluidity and permeability. Disturbances of plasma mem-
brane permeability largely contribute to trypomastigote
death. Numerous metabolites from natural origin includ-
ing soulamarin, dermaseptins and phylloseptins have been
reported to trigger such death mechanism [20, 23]. More-
over, drugs in clinical use for leishmaniasis such as milte-
fosine and amphotericin B are known to alter the
permeability of plasma membrane [48, 49]. In this study,
T. cruzi trypomastigotes treated with ergosterol suffered a
rapid depolarization of the mitochondrial membrane po-
tential probably by a direct accumulation in the mitochon-
dria or as a secondary effect of the disturbance in plasma
membrane permeability. Corroborating the previous hy-
pothesis, exogenous ergosterol, but not cholesterol, is cap-
able of abolishing the ketoconazole-induced massive
swelling of the mitochondria [50].
Under conditions of permeability disturbance and loss
of mitochondrial potential, the single mitochondria of T.
cruzi may produce excessive ROS [51–53]. Our results
demonstrated that ergosterol-treated trypomastigotes did
not present significant alteration in ROS levels. These data
suggest that exogenous supplementation of ergosterol
may target the mitochondria and act as ROS scavengers,
as indicated by a recent finding reported elsewhere [46].
Additionally, Leishmania (Leishmania) donovani parasites
that are CYP51-defective constitutively present low ergos-
terol levels and higher susceptibility to oxidative stress in-
duced by antimony [54]. The cell viability is increased
during exposure to antimony by in vitro supplementation
of ergosterol [45]. Therefore, we suggest that oxidative
stress may not be contribute to the mechanism of action
of ergosterol in T. cruzi parasites.
Conclusion
The basidiomycete mushroom Pleurotus salmoneostra-
mineus demonstrated to be an interesting and underex-
plored natural source for antiparasitic metabolites.
Disturbances in the permeability of plasma membrane
and loss of mitochondrial membrane potential without
involvement of oxidative stress were pointed as initial
mechanisms of action of ergosterol against T. cruzi.
Although ergosterol is a constituent of the plasma
membrane of T. cruzi, it is also effective to eliminate the
parasite. The compound is a low cytotoxic substance
that may be useful as scaffold for future synthesis of new
derivatives against Trypanosoma cruzi.
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